Autonomix Medical

What Autonomix Medical does

Autonomix Medical is a pre-revenue, NASDAQ-listed medical device company developing a first-in-class catheter-based microchip sensing array that enables real-time, transvascular nerve detection combined with radiofrequency (RF) ablation. The core technology centers on a proprietary 1×2 mm microchip with embedded sensing and processing electronics that achieves detection thresholds below 5 microvolts using prototype electrodes as small as 0.02 mm × 0.03 mm, and supports 360-degree multichannel sensing for nerve mapping. The platform is delivered through a minimally invasive, transvascular approach and is positioned by the company as enabling physicians to sense, treat, and verify nerve ablation intra-procedurally.

The company's initial clinical focus is pancreatic cancer pain via the first-in-human PoC 1 study, with positive reported outcomes including 100% zero opioid use at three months and 65.6% mean pain reduction on the VAS scale among responders. A follow-on PoC 2 study expands into additional visceral cancers (gall bladder, liver, bile duct) and earlier-stage pancreatic cancer patients. Planned indications extend into cardiology (renal denervation for hypertension, pulmonary nerve therapies, atrial fibrillation), pulmonology, gastroenterology, and chronic pain. The intellectual property portfolio comprises 18 patent families and more than 120 issued or pending applications globally, with expirations extending into the late 2030s, and includes recently granted U.S. Patent No. 12,544,131 and European Patent No. EP4230133.

Autonomix has not yet received regulatory clearance to market its technology in the United States. The intended business model is direct hospital sales of a capital-and-consumable catheter-based platform targeting interventional radiology suites, catheterization labs, and academic cancer centers, with hardware sales as the primary revenue stream. The company has no disclosed revenue and is dependent on periodic equity financings — including a $5.0 million private placement in November 2025 and a $2.5 million warrant exercise in July 2025 — to fund clinical development and operations.

Name

Autonomix Medical

Legal name

Autonomix Medical, Inc.

Website

https://autonomix.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Autonomix Medical is a pre-revenue medical device company developing a first-in-class catheter-based microchip sensing platform for real-time nerve detection and radiofrequency ablation. The company targets pancreatic cancer pain initially, with planned expansion into cardiology, pulmonology, and gastroenterology.

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Electrophysiology Mapping & Ablation Systems (HLAHAFAD)

Keywords

• Nerve ablation devices
• Transvascular denervation
• Neuromodulation catheters
• Interventional pain management
• Renal denervation systems

Headquarters

HQ city

Excelsior

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Medical Device Sales: Autonomix is a pre-revenue medical device company developing a catheter-based nerve ablation platform. The company expects to commercialize its technology following regulatory approval. Initial focus is on pancreatic cancer pain treatment with plans to expand across cardiology, pulmonology, gastroenterology, and chronic pain applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Autonomix Medical is developing a first-in-class catheter-based microchip sensing array platform that enables real-time intra-procedural nerve mapping, RF ablation, and verification through a minimally invasive transvascular approach. The proprietary system is initially targeted at intractable pancreatic cancer pain, with planned expansion into cardiology (renal denervation, atrial fibrillation), pulmonology, gastroenterology, and chronic pain management. The technology remains investigational and is not yet cleared for marketing in the United States.

Product overview

Autonomix Medical is developing a first-in-class, breakthrough platform technology described as 'the world's first GPS for the nervous system.' The platform consists of a catheter-based microchip sensing array that detects neural signals with ultra-high sensitivity (below 5 µV), proprietary RF ablation technology for targeted nerve denervation, and real-time verification capabilities. The system is delivered through a minimally invasive, transvascular approach. The core platform is initially focused on pancreatic cancer pain treatment via the PoC 1 and PoC 2 proof-of-concept clinical trials, with expansion opportunities into cardiology (renal denervation, pulmonary nerve therapies, atrial fibrillation), pulmonology, and gastroenterology. The technology is investigational and has not yet received regulatory marketing clearance.

Differentiator

Problem solved

Functional benefit

Products and services

• Nerve-Sensing and Transvascular Denervation Platform First-in-class catheter-based platform that senses nerve activity in real time, guides RF ablation delivery, and verifies successful nerve denervation during minimally invasive transvascular procedures. Targeted at interventional pain management, cardiology (renal denervation, atrial fibrillation), pulmonology, and gastroenterology for hospitals and interventional specialists.
• Catheter-Based Microchip Sensing Array Proprietary 1x2 mm catheter-based microchip with embedded sensing and processing electronics positioned millimeters from target nerves. Achieves detection thresholds below 5 microvolts using prototype electrodes as small as 0.02 mm x 0.03 mm, enabling high-fidelity neural signal capture at the point of detection for hospital interventional use.
• Radio Frequency (RF) Ablation Technology Proprietary RF ablation technology that targets and disrupts nerve signaling pathways by delivering targeted ablation transvascularly through vessel walls to disable nerves responsible for pain transmission. Used together with the catheter-based microchip sensing array to enable real-time ablation guidance and verification for hospital interventional procedures.
• PoC 1 Proof-of-Concept Study (Pancreatic Cancer Pain) First-in-human clinical trial validating Autonomix's nerve ablation platform for treatment of severe, intractable pancreatic cancer pain. Demonstrated sustained pain reduction, 100% zero opioid use, and quality of life gains with no device or procedure-related serious adverse events in responding patients.
• PoC 2 Proof-of-Concept Expansion Study Follow-on clinical study expanding the nerve ablation platform beyond severe pancreatic cancer pain to additional visceral cancers that signal pain through the Celiac Plexus (gall bladder, liver, bile duct) and earlier-stage pancreatic cancer patients with moderate to severe pain, doubling the potential addressable market.
• Standalone Neural Sensing Platform for Renal Denervation Standalone neural sensing platform under development for cardiology applications, specifically renal denervation procedures for uncontrolled hypertension. Leverages Autonomix's core real-time nerve sensing technology to address autonomic nerve dysfunction in cardiovascular disease.

Quantifiable outcome

• 100% of responding patients were opioid-free at 3-month post-procedure follow-up
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Recor Medical: Developer of the Paradise Ultrasound Renal Denervation System, the first FDA-approved RDN device for hypertension. Directly comparable to Autonomix's planned renal denervation program and shares the same catheter-based intravascular nerve-targeting approach.
• Ablative Solutions: Developer of the Peregrine System for chemical renal denervation via the adventitial route. Competes with Autonomix in the hypertension RDN market with a catheter-based nerve-targeting approach.

Broad incumbents

• Medtronic: Markets the Symplicity Spyral renal denervation system and a broad electrophysiology portfolio. Competes with Autonomix in transvascular nerve modulation for hypertension and AFib, with far greater clinical data, capital, and commercial scale.
• AbbVie (Allergan Aesthetics): Acquired Autonomix CEO's prior company Soliton for $550M. Represents the type of strategic acquirer relevant to Autonomix; also broad incumbent in medical device/aesthetics with electrophysiology adjacencies.
• Boston Scientific: Owns the Watchman left atrial appendage closure device invented by Autonomix CMO Dr. Robert Schwartz. A relevant incumbent in cardiac electrophysiology and interventional cardiology that could be a future acquirer or partner for Autonomix's cardiology expansion.
• Penumbra: Public thrombectomy company that has expanded into interventional pain via the REAL system. Relevant comparable for catheter-based interventional pain management, Autonomix's initial focus.

Emerging players

• SoniVie: Clinical-stage company developing ultrasound-based renal denervation (TIVUS system). An emerging peer competing for the same hypertension RDN market with a different energy modality.
• Axonics: Public neuromodulation company commercializing sacral and tibial nerve stimulation devices. Comparable as a small-cap public neuromodulation pure-play, though focused on different anatomical targets.
• CardioFocus: Developer of catheter-based ablation systems (HeartLight) for atrial fibrillation. Comparable in catheter-based cardiac electrophysiology and ablation, with overlap in Autonomix's planned AFib expansion.
• Verve Medical: Early-stage company developing non-surgical renal denervation for hypertension. Comparable as a small, catheter-based nerve-targeting player in the same RDN end market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/AutonomixMed
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/autonomix-medical-inc
• Instagraminstagram.com/autonomixmedical

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds7 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Autonomix Medical